Meningococcus vaccines
US-2018214531-A1 · Aug 2, 2018 · US
Modified meningococcal fHbp polypeptides
US11066450B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11066450-B2 |
| Application number | US-201515319651-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 16, 2015 |
| Priority date | Jul 17, 2014 |
| Publication date | Jul 20, 2021 |
| Grant date | Jul 20, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The inventors have identified residues within variant 2 and variant 3 of meningococcal fHbp which can be modified to enhance their properties.
First claim
Opening claim text (preview).
The invention claimed is: 1. A polypeptide comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 5, wherein the amino acid sequence differs from SEQ ID NO: 5 by S32V, L123R, and E240A substitutions numbered relative to SEQ ID NO: 5. 2. The polypeptide of claim 1 , wherein the amino acid sequence comprises SEQ ID NO: 50. 3. An immunogenic composition comprising a pharmaceutically acceptable carrier, a polypeptide according to claim 1 , and optionally an adjuvant.
Assignees
Inventors
Classifications
- C07K14/22Primary
from Neisseriaceae (F) · CPC title
Neisseria · CPC title
fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title
humoral response · CPC title
Antibacterial agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11066450B2 cover?
- The inventors have identified residues within variant 2 and variant 3 of meningococcal fHbp which can be modified to enhance their properties.
- Who is the assignee on this patent?
- Glaxosmithkline Biologicals Sa
- What technology area does this patent fall under?
- Primary CPC classification C07K14/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).